Literature DB >> 12045778

Natural history of C282Y homozygotes for hemochromatosis.

John P Wojcik1, Mark R Speechley, Ann E Kertesz, Subrata Chakrabarti, Paul C Adams.   

Abstract

PURPOSE: To study the clinical outcomes of subjects who are homozygous for the C282Y mutation of the hemochromatosis gene. SUBJECTS AND METHODS: All patients referred to a tertiary referral centre for hemochromatosis were included. The study also included 16 C282Y homozygotes detected in a population screening study.
RESULTS: The study comprised 277 C282Y homozygotes, including 16 nonexpressing C282Y homozygotes. The mean follow-up period was 7.3 years (range zero to 44 years). The actuarial survival rates of C282Y homozygotes at five, 10 and 20 years were 95%, 93% and 66%, respectively. Life-threatening diseases (cirrhosis, hepatocellular carcinoma, diabetes, heart disease) were present in 36% of male C282Y homozygotes and 19% of female C282Y homozygotes. Cirrhosis of the liver and diabetes were the major clinical symptoms affecting long term survival. Only one nonexpressing homozygote required venesection therapy during the follow-up period.
CONCLUSIONS: Long term survival is excellent in C282Y homozygotes diagnosed and treated before the development of cirrhosis and diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12045778     DOI: 10.1155/2002/161569

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  15 in total

1.  Clinical guidelines: HFE hemochromatosis-screening, diagnosis and management.

Authors:  James C Barton; Paul C Adams
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-09       Impact factor: 46.802

2.  The impact of polyether chain length on the iron clearing efficiency and physiochemical properties of desferrithiocin analogues.

Authors:  Raymond J Bergeron; Neelam Bharti; Jan Wiegand; James S McManis; Shailendra Singh; Khalil A Abboud
Journal:  J Med Chem       Date:  2010-04-08       Impact factor: 7.446

3.  The design, synthesis, and evaluation of organ-specific iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2006-11-30       Impact factor: 7.446

Review 4.  A diagnostic approach to hemochromatosis.

Authors:  Anthony S Tavill; Paul C Adams
Journal:  Can J Gastroenterol       Date:  2006-08       Impact factor: 3.522

5.  (S)-4,5-dihydro-2-(2-hydroxy-4-hydroxyphenyl)-4-methyl-4-thiazolecarboxylic acid polyethers: a solution to nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; John R T Vinson; Hua Yao; Neelam Bharti; James R Rocca
Journal:  J Med Chem       Date:  2006-05-04       Impact factor: 7.446

Review 6.  Molecular and clinical aspects of iron homeostasis: From anemia to hemochromatosis.

Authors:  Manfred Nairz; Günter Weiss
Journal:  Wien Klin Wochenschr       Date:  2006-08       Impact factor: 1.704

7.  Desferrithiocin analogues and nephrotoxicity.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-09-13       Impact factor: 7.446

8.  Design, synthesis, and testing of non-nephrotoxic desazadesferrithiocin polyether analogues.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti; Shailendra Singh
Journal:  J Med Chem       Date:  2008-06-06       Impact factor: 7.446

9.  Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; Shailendra Singh; James R Rocca
Journal:  J Med Chem       Date:  2007-06-12       Impact factor: 7.446

10.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.